Clinical trial
NGR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens.
Antitumour activity defined as Progression Free Survival.
| Category | Value |
|---|---|
| Study start date | 2007-01-24 |